Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy

Schwager, Zachary; Laird, Mary E.; Latkowski, Jo‐Ann

doi:10.1016/j.jdcr.2017.10.019

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitiligo is a common adverse effect of checkpoint inhibitors, thought to result from an immune attack on normal melanocytes, as in de novo vitiligo . A case of depigmentation of cutaneous nevi after administration of ipilimumab and nivolumab and another case after the use of pembrolizumab for metastatic melanoma have been reported.…”

Section: Discussionmentioning

confidence: 99%

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

et al. 2019

View full text Add to dashboard Cite

“…With respect to naevus change in those undergoing immuno- and/or targeted therapies, several case reports have described hypopigmentation of naevi, regression/involution of naevi with and without the halo effect and, in a few cases, appearance of new naevi [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ]. An Italian study of 11 patients receiving dabrafenib observed the appearance of new naevi in 4/11 patients, and hyperkeratosis/hyperpigmentation in 6/11 patients [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series

Sanjida

Betz‐Stablein

Atkinson

et al. 2022

Cancers

View full text Add to dashboard Cite

Immunotherapies and targeted therapies have shown significant benefits for melanoma survival in the clinical trial setting. Much less is known about the characteristics and associated outcomes of those receiving such therapies in real-world settings. This study describes the characteristics of patients with advanced melanoma receiving immuno- and/or targeted therapies in a real-world setting. This prospective cohort study enrolled participants aged >18 years, diagnosed with advanced melanoma and currently undergoing immuno- and/or targeted therapies outside a clinical trial for follow-up with three-dimensional (3D) total-body imaging. Participants (n = 41) had a mean age of 62 years (range 29–86), 26 (63%) were male and the majority (n = 26, 63%) had ≥2 comorbidities. After a median of 39 months (range 1–52) follow-up, 59% (n = 24/41) of participants were alive. Despite multiple co-morbidities, the survival of participants with advanced melanoma treated using immuno- and/or targeted therapies was similar or better in our real-world setting compared to those treated in clinical trials using similar therapies. Larger studies powered to evaluate phenotypic and socio-economic characteristics, as well as specific comorbidities associated with survival in a real-world setting, are required to help determine those who will most benefit from immuno- and/or targeted therapies.

show abstract

“…Immunotherapy-induced halo nevus reaction is reported to occur less frequently than vitiligo. Similar to what happen in vitiligo, the disappearance of pigmented lesions may be related to the onset of an immune response towards antigens shared by melanocytes and melanoma cells [ 31 ].…”

Section: Halo Nevusmentioning

confidence: 99%

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review

Burzi

Alessandrini

Quaglino

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy

Cited by 9 publications

References 11 publications

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review

Contact Info

Product

Resources

About